Tommy Wu, BA

Articles by Tommy Wu, BA

Real-World Economic Value of a 21-Gene Assay in Early-Stage Breast Cancer

ByStanley E. Waintraub, MD,Donna McNamara, MD,Deena Mary Atieh Graham, MD,Andrew L. Pecora, MD,John Min, BS,Tommy Wu, BA,Hyun Gi Noh, MSC,Jacqueline Connors, RN, OCN,Ruth Pe Benito, MPH, BS,Kelly Choi, MD,Eric Schultz, BS,Stuart L. Goldberg, MD

December 20th 2017

Universal gene expression profiling of patients with stage II breast cancer resulted in outpatient savings of $11,000 (inclusive of testing costs) within 6 months of initiation of medical therapy.

Latest Updated Articles

Real-World Economic Value of a 21-Gene Assay in Early-Stage Breast Cancer
Published: December 20th 2017 | Updated:

Tommy Wu, BA

Articles by Tommy Wu, BA

Real-World Economic Value of a 21-Gene Assay in Early-Stage Breast Cancer

Latest Updated Articles

Trending on AJMC

Newly Unveiled ACA Premiums Show 26% Average Increase Before Subsidy Expiration

Boosting RSV Vaccination in Older Adults Could Save Thousands

FDA Guidance to Remove One of the Largest Barriers to Biosimilar Development

Real-World Data Key to Optimizing CAR T-Cell Therapy Delivery, Outcomes

New PBM Laws Seek to Protect Independent Pharmacies but Could Raise Costs, Limit Patient Access